Cellivate Technologies raises $1 million in seed round

Bio-tech startup Cellivate Technologies has successfully raised $1 million in a seed round. This funding round was led by Antler with participation from Venture Catalysts, Hatcher+, and We Founder Circle.

Funding Utilization

Cellivate plans to use the funds to:

  • Accelerate research and development efforts
  • Scale up production of innovative products
  • Expand market reach

About Cellivate Technologies

Founded by Viknish Krishnan Kutty, Cellivate Technologies focuses on developing innovative solutions for cell culture and biomanufacturing. The company’s flagship products include:

  • Advanced Microcarriers: For scaling up cell growth
  • Novel Cell-Based Serum: Designed to replace fetal bovine serum

Market Potential

The cell culture market, particularly in microcarriers and serum, is projected to reach $33 billion by 2030. Cellivate’s products aim to:

  • Reduce costs
  • Increase efficiency
  • Address ethical concerns in cell culture processes

Impact on Industry

Cellivate’s advancements in cell culture and biomanufacturing technologies are expected to reduce dependence on animal-derived products. This shift can potentially lead to more ethical and sustainable practices in the industry.

Key Highlights

  • Funding: $1 million seed round
  • Lead Investor: Antler
  • Participants: Venture Catalysts, Hatcher+, We Founder Circle
  • Product Focus: Microcarriers, cell-based serum alternatives
  • Market Potential: $33 billion by 2030

This investment marks a significant step for Cellivate Technologies in its mission to revolutionize cell culture and biomanufacturing processes.